Iżrael - Ebrajk - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Iżrael - Ebrajk - Ministry of Health

הייר ליין הכל לספר 2001 בעמ - לחות לשיער

Iżrael - Ebrajk - Ministry of Health

בית היופי ג'יזל - שיפור מראה העור

Iżrael - Ebrajk - Ministry of Health

דנשר (1963) בעמ - המרצת עור הקרקרפת

Iżrael - Ebrajk - Ministry of Health

דנשר (1963) בעמ - טיפוח עור הקרקפת

Iżrael - Ebrajk - Ministry of Health

נאוטק קבוצת קורדן בעמ - מרגיע ומאזן את העור

Iżrael - Ebrajk - Ministry of Health

גדעון קוסמטיקס בעמ - ניקוי וטיפוח שיער דליל

Iżrael - Ebrajk - Ministry of Health

גדעון קוסמטיקס בעמ - טיפוח שיער דליל

Iżrael - Ebrajk - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Iżrael - Ebrajk - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative